Get the Stockscreener App
0.684
4.67%
-0.0335
After Hours:
.68
-0.004
-0.58%
Enlivex Ltd stock is traded at $0.684, with a volume of 593.48K.
It is down -4.67% in the last 24 hours and down -23.02% over the past month.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
See More
Previous Close:
$0.7175
Open:
$0.691
24h Volume:
593.48K
Relative Volume:
1.13
Market Cap:
$164.88M
Revenue:
-
Net Income/Loss:
$1.24B
P/E Ratio:
0.0268
EPS:
25.475
Net Cash Flow:
$-31.80M
1W Performance:
-2.91%
1M Performance:
-23.02%
6M Performance:
-24.00%
1Y Performance:
-29.85%
1-Day Range:
$0.66
$0.70
1-Week Range:
$0.66
$0.7428
52-Week Range:
$0.66
$2.10
Enlivex Ltd Stock (ENLV) Company Profile
Compare ENLV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Ltd
|
0.684 | 172.95M | 0 | 1.24B | -31.80M | 25.48 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enlivex Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Ltd Stock (ENLV) Latest News
ENLV Q4 2025 Earnings: Significant EPS Miss Amid Development Stage CostsProfit Cycle Analysis - Newser
Enlivex Ltd. (ENLV) Slides Slightly as Shares Hover Near Key Support LevelFear Greed Index - Newser
Enlivex Ltd expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Enlivex (ENLV) Edges Higher After Testing Key Support at $0.69Ichimoku TK Cross - Newser
ENLV Q1'26 Earnings: EPS estimate is (0.02) USD - TradingView
Enlivex Doses First US Patient in Phase 2b Knee Osteoarthritis Trial - Moomoo
Enlivex (ENLV) Begins Phase 2b Clinical Trial for Osteoarthritis Treatment - GuruFocus
Enlivex doses first U.S. patient in knee osteoarthritis trial - Investing.com UK
Enlivex Doses First U.S. Patient in Phase 2b Allocetra Trial for Knee Osteoarthritis - TipRanks
Enlivex doses first U.S. patient in knee osteoarthritis trial By Investing.com - Investing.com Canada
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis - The Manila Times
First U.S. patient dosed in Enlivex (Nasdaq: ENLV) Phase 2b knee OA trial - Stock Titan
Enlivex Ltd Announces Dosing of First Patient in the United States as Part of Phase 2B Trial of Allocetra in Age-Related Primary Moderate-To-Severe Knee Osteoarthritis - marketscreener.com
Enlivex receives Nasdaq minimum bid price deficiency notice - Investing.com India
Enlivex Faces Nasdaq Minimum Bid Price Deficiency After Shares Fall Below $1 Threshold - TipRanks
Enlivex receives Nasdaq minimum bid price deficiency notice By Investing.com - Investing.com South Africa
Enlivex announces receipt of Nasdaq minimum bid price notification - marketscreener.com
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification - The Manila Times
Enlivex Ltd. Receives Nasdaq Notice for Minimum Bid Price Non-Compliance - Quiver Quantitative
Enlivex (NASDAQ: ENLV) gets Nasdaq notice over sub-$1 bid price and listing risk - Stock Titan
ENLV Q1'26 Earnings: revenue estimate is 0 USD - TradingView
Enlivex Therapeutics stock (IL0011283620): Recent price drop and analyst views - AD HOC NEWS
Enlivex advances Allocetra while expanding into prediction markets - Proactive financial news
TradingKey - TradingKey
Enlivex Ltd. (NASDAQ: ENLV) registers 23.33M shares for resale by noteholder - Stock Titan
Enlivex Ltd Share PriceENLV, RNS News, Articles, Quotes, & Charts (NASDAQ:ENLV) - Proactive financial news
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange - The Manila Times
Enlivex’s $567M RAIN treasury asset gains a new market on HTX - Stock Titan
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million - The Manila Times
Enlivex Ltd.: Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million - FinanzNachrichten.de
$567M in RAIN: Enlivex taps option priced 55% below April 27 close - Stock Titan
Enlivex Therapeutics (ENLV) price target decreased by 30.00% to 7.14 - MSN
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Enlivex (ENLV) price target increased by 53.85% to 20.40 - MSN
ENLV (Enlivex Ltd. Ordinary Shares) posts sharply wider Q4 2025 loss than expected, shares drop 3.26% on dismal earnings.Barrier to Entry - Cổng thông tin điện tử Tỉnh Sơn La
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress - The Manila Times
New knee osteoarthritis data from Enlivex heads to OARSI 2026 - Stock Titan
Enlivex receives Danish approval for knee osteoarthritis trial By Investing.com - Investing.com India
Enlivex Ltd.: Fundamental Analysis and Financial Ratings | ENLV | IL0011319527 - marketscreener.com
Enlivex Ltd. (ENLV) registers 23.3M conversion shares from $21M note - Stock Titan
Enlivex (ENLV) Secures Approval for Phase 2b Osteoarthritis Clin - GuruFocus
Enlivex Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):